Among second-line treatments for sarcoidosis, methotrexate is safer and associated with a lower risk of hospitalization, intensive care, the need for breathing support, and death compared to mycophenolate mofetil (MMF), according to a large real-world study. Methotrexate also showed a trend toward better efficacy and similar safety…